Patent ID: 7883904
Filing Date: 2011-02-08
Classification: G01N,Y10S

Abstract:
1. A method of assessing the severity of non-alcoholic fatty liver disease in a subject, the method comprising: obtaining a bodily sample from the subject, wherein the bodily sample is selected from the group consisting of blood, plasma, and serum; measuring the level of caspase-3 generated cytokeratin-18 fragments which are cleaved at aspartic acid residue 396 in the bodily sample; and correlating the level of caspase-3 generated cytokeratin-18 fragments which are cleaved at aspartic acid residue 396 with the severity of non-alcoholic fatty liver disease in the subject, wherein the higher the measured level of caspase-3 generated cytokeratin-18 fragments which are cleaved at aspartic acid residue 396 in the bodily sample compared to a predetermined value, the more severe the non-alcoholic fatty liver disease in the subject.